Home โบ Myelofibrosis
Myelofibrosis clinical trials recruiting in the U.S.
58 studies for Myelofibrosis are recruiting participants at sites across the United States.
Cities with the most studies
- New York City, NY21 studies
- Houston, TX20 studies
- Boston, MA13 studies
- Durham, NC13 studies
- Columbus, OH12 studies
- Seattle, WA12 studies
- Tampa, FL11 studies
- Nashville, TN11 studies
- Miami, FL11 studies
- Salt Lake City, UT11 studies
- Ann Arbor, MI10 studies
- Atlanta, GA10 studies
- Baldwin Park, CA10 studies
- St. Louis, MO9 studies
- Winston-Salem, NC9 studies
- Cleveland, OH9 studies
- Chicago, IL8 studies
- Birmingham, AL8 studies
- Baltimore, MD8 studies
- Mountain View, CA7 studies
- Irvine, CA6 studies
- Kansas City, MO6 studies
- Philadelphia, PA6 studies
- Los Angeles, CA6 studies
- Charlotte, NC5 studies
- Cincinnati, OH5 studies
- Portland, OR5 studies
- Denver, CO5 studies
- Sacramento, CA4 studies
- Queens, NY4 studies
- Gilbert, AZ4 studies
- Minneapolis, MN4 studies
- Washington, DC4 studies
- Dallas, TX4 studies
- Jacksonville, FL4 studies
- New Haven, CT4 studies
- Milwaukee, WI4 studies
- Edison, NJ4 studies
- Kansas City, KS3 studies
- Richmond, VA3 studies
By state
- Alabama8 studies
- Arizona8 studies
- California22 studies
- Colorado7 studies
- Connecticut5 studies
- Florida16 studies
- Georgia10 studies
- Illinois9 studies
- Iowa3 studies
- Kansas8 studies
- Maryland10 studies
- Massachusetts14 studies
- Michigan12 studies
- Minnesota7 studies
- Missouri9 studies
- New Jersey6 studies
- New York23 studies
- North Carolina19 studies
- Ohio18 studies
- Oregon7 studies
- Pennsylvania8 studies
- South Carolina4 studies
- Tennessee11 studies
- Texas21 studies
- Utah11 studies
- Virginia7 studies
- Washington12 studies
- Wisconsin5 studies
Recently updated studies
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Nov 13, 2026 ยท NCT07441694A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Nov 13, 2026 ยท NCT07357727A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Nov 12, 2026 ยท NCT06343805A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Nov 10, 2026 ยท NCT06351631A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Nov 6, 2026 ยท NCT07623161Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Nov 4, 2026 ยท NCT06517875A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Oct 29, 2026 ยท NCT07469891Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RecruitingObservational study
Ages 18 to 120 ยท All sexes ยท Updated Oct 28, 2026 ยท NCT01137643A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Oct 27, 2026 ยท NCT06661915A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Oct 27, 2026 ยท NCT07849231AlloHCT With PegINFa for Myelofibrosis
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Oct 27, 2026 ยท NCT05535764Selinexor and Pacritinib in JAK Inhibitor-naรฏve MF Patients With Cytopenias
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Oct 27, 2026 ยท NCT07447817Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Oct 26, 2026 ยท NCT07281781CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RecruitingPhase 2Healthy volunteers welcome
Ages 18 to 75 ยท All sexes ยท Updated Oct 23, 2026 ยท NCT06059391A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 75 ยท All sexes ยท Updated Oct 23, 2026 ยท NCT07020533Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Oct 22, 2026 ยท NCT05320198Therapeutic RSK1 Targeting in Myeloid Malignancies
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Oct 21, 2026 ยท NCT07379125Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Oct 21, 2026 ยท NCT05423691Pacritinib Effectiveness in Real-world Settings
RecruitingObservational study
Ages 18 and older ยท All sexes ยท Updated Oct 21, 2026 ยท NCT07774455Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Oct 19, 2026 ยท NCT07521046Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
RecruitingPhase 2
Ages 18 to 75 ยท All sexes ยท Updated Oct 19, 2026 ยท NCT07228624Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Oct 9, 2026 ยท NCT07128381Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RecruitingEarly phase 1
Ages 18 and older ยท All sexes ยท Updated Oct 5, 2026 ยท NCT06398457A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Oct 2, 2026 ยท NCT04176198Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 17, 2026 ยท NCT04282187From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.